JP7042816B2 - レプチン受容体をアンタゴナイズする抗原結合性タンパク質 - Google Patents

レプチン受容体をアンタゴナイズする抗原結合性タンパク質 Download PDF

Info

Publication number
JP7042816B2
JP7042816B2 JP2019523865A JP2019523865A JP7042816B2 JP 7042816 B2 JP7042816 B2 JP 7042816B2 JP 2019523865 A JP2019523865 A JP 2019523865A JP 2019523865 A JP2019523865 A JP 2019523865A JP 7042816 B2 JP7042816 B2 JP 7042816B2
Authority
JP
Japan
Prior art keywords
antibody
lepr
amino acid
seq
acid sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2019523865A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020504078A5 (OSRAM
JP2020504078A (ja
Inventor
ジェスパー グロマダ，
パナイオティス ステーヴィス，
ジュディス アルタレホス，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Regeneron Pharmaceuticals Inc
Original Assignee
Regeneron Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharmaceuticals Inc filed Critical Regeneron Pharmaceuticals Inc
Publication of JP2020504078A publication Critical patent/JP2020504078A/ja
Publication of JP2020504078A5 publication Critical patent/JP2020504078A5/ja
Priority to JP2021206917A priority Critical patent/JP2022031969A/ja
Application granted granted Critical
Publication of JP7042816B2 publication Critical patent/JP7042816B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2869—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against hormone receptors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/72—Receptors; Cell surface antigens; Cell surface determinants for hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
JP2019523865A 2016-11-08 2017-11-08 レプチン受容体をアンタゴナイズする抗原結合性タンパク質 Active JP7042816B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2021206917A JP2022031969A (ja) 2016-11-08 2021-12-21 レプチン受容体をアンタゴナイズする抗原結合性タンパク質

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662419062P 2016-11-08 2016-11-08
US62/419,062 2016-11-08
PCT/US2017/060690 WO2018089532A1 (en) 2016-11-08 2017-11-08 Antigen-binding proteins that antagonize leptin receptor

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2021206917A Division JP2022031969A (ja) 2016-11-08 2021-12-21 レプチン受容体をアンタゴナイズする抗原結合性タンパク質

Publications (3)

Publication Number Publication Date
JP2020504078A JP2020504078A (ja) 2020-02-06
JP2020504078A5 JP2020504078A5 (OSRAM) 2020-12-10
JP7042816B2 true JP7042816B2 (ja) 2022-03-28

Family

ID=60409473

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2019523865A Active JP7042816B2 (ja) 2016-11-08 2017-11-08 レプチン受容体をアンタゴナイズする抗原結合性タンパク質
JP2021206917A Pending JP2022031969A (ja) 2016-11-08 2021-12-21 レプチン受容体をアンタゴナイズする抗原結合性タンパク質
JP2023076083A Active JP7611292B2 (ja) 2016-11-08 2023-05-02 レプチン受容体をアンタゴナイズする抗原結合性タンパク質
JP2024088870A Pending JP2024109952A (ja) 2016-11-08 2024-05-31 レプチン受容体をアンタゴナイズする抗原結合性タンパク質

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2021206917A Pending JP2022031969A (ja) 2016-11-08 2021-12-21 レプチン受容体をアンタゴナイズする抗原結合性タンパク質
JP2023076083A Active JP7611292B2 (ja) 2016-11-08 2023-05-02 レプチン受容体をアンタゴナイズする抗原結合性タンパク質
JP2024088870A Pending JP2024109952A (ja) 2016-11-08 2024-05-31 レプチン受容体をアンタゴナイズする抗原結合性タンパク質

Country Status (28)

Country Link
US (3) US10550192B2 (OSRAM)
EP (2) EP4613772A3 (OSRAM)
JP (4) JP7042816B2 (OSRAM)
KR (1) KR102563568B1 (OSRAM)
CN (1) CN110167965A (OSRAM)
AU (2) AU2017359439B2 (OSRAM)
CA (1) CA3043365A1 (OSRAM)
CL (3) CL2019001263A1 (OSRAM)
CO (1) CO2019004672A2 (OSRAM)
DK (1) DK3538554T3 (OSRAM)
EA (1) EA201991075A1 (OSRAM)
ES (1) ES3040144T3 (OSRAM)
FI (1) FI3538554T3 (OSRAM)
HR (1) HRP20251165T1 (OSRAM)
IL (2) IL266426B (OSRAM)
LT (1) LT3538554T (OSRAM)
MA (1) MA45801B1 (OSRAM)
MX (2) MX2019005397A (OSRAM)
MY (2) MY203682A (OSRAM)
PH (1) PH12019500988A1 (OSRAM)
PL (1) PL3538554T3 (OSRAM)
PT (1) PT3538554T (OSRAM)
RS (1) RS67214B1 (OSRAM)
SG (1) SG10201913470SA (OSRAM)
SI (1) SI3538554T1 (OSRAM)
SM (1) SMT202500327T1 (OSRAM)
UA (1) UA127678C2 (OSRAM)
WO (1) WO2018089532A1 (OSRAM)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI752920B (zh) 2015-10-12 2022-01-21 美商再生元醫藥公司 活化瘦素受體的抗原結合蛋白
FI3538554T3 (fi) 2016-11-08 2025-09-24 Regeneron Pharma Antigeeniä sitovia proteiineja, jotka antagonisoivat leptiinireseptoria
AU2018390811A1 (en) 2017-12-18 2020-07-02 Regeneron Pharmaceuticals, Inc. Bispecific antigen binding molecules that bind leptin receptor and/or GP130, and methods of use thereof
CA3094400A1 (en) 2018-04-06 2019-10-10 Regeneron Pharmaceuticals, Inc. A leptin receptor agonist antibody for use in treating a metabolic dysfunction or hypoleptinemia
WO2020016160A1 (en) * 2018-07-16 2020-01-23 INSERM (Institut National de la Santé et de la Recherche Médicale) Method to treat neurological diseases
MX2021007394A (es) 2018-12-18 2021-07-15 Regeneron Pharma Composiciones y metodos para aumentar el peso corporal y la masa muscular magra mediante el uso de antagonistas contra el receptor de leptina, gdf8 y activina a.
KR20210095781A (ko) 2020-01-24 2021-08-03 주식회사 에이프릴바이오 항원결합 단편 및 생리활성 이펙터 모이어티로 구성된 융합 컨스트럭트를 포함하는 다중결합항체 및 이를 포함하는 약학조성물
US20230263673A1 (en) * 2020-07-17 2023-08-24 Sumitomo Seika Chemicals Co., Ltd. Absorber
PE20231657A1 (es) * 2020-09-15 2023-10-17 Regeneron Pharma Uso de agonistas de lepr para el dolor
CN118436632B (zh) * 2024-07-05 2024-08-30 四川大学华西第二医院 Teriflunomide在制备预防和/或治疗原发性纤毛不动综合征的药物中的用途

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2000504938A (ja) 1996-01-16 2000-04-25 ザ ロックフェラー ユニヴァーシティ Ｄｂ、レプチンのレセプター、そのレセプターをコードする核酸、及びこれらの使用
JP2001501444A (ja) 1995-11-27 2001-02-06 ミレニウム ファーマシューティカルズ インク． Ｏｂ受容体ならびに体重障害の診断および治療の方法
JP2007536212A (ja) 2003-11-17 2007-12-13 ルートヴィヒ マクシミリアン ウニヴェルジテート レプチンアンタゴニストおよびレプチン定量測定方法

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5643748A (en) 1994-09-14 1997-07-01 Progenitor, Inc. HU-B1.219, a novel human hematopoietin receptor
US6451523B1 (en) 1994-09-14 2002-09-17 Interneuron Pharmaceuticals, Inc. Detection of a leptin receptor variant and methods for regulating obesity
US5856098A (en) 1994-09-14 1999-01-05 Progenitor, Inc. Detection of a leptin receptor variant
US5912123A (en) 1994-09-14 1999-06-15 Progenitor, Inc. Detection of the leptin receptor in reproductive organs and methods for regulating reproductive biology
US6977240B1 (en) 1995-11-27 2005-12-20 Millenium Pharmaceuticals, Inc. Methods of using the OB receptor antibodies to treat bodyweight disorders
US20050019325A1 (en) 1996-01-08 2005-01-27 Carter Paul J. WSX receptor agonist antibodies
ATE307887T1 (de) 1996-01-08 2005-11-15 Genentech Inc Ob-rezeptor und liganden
AU2476301A (en) 1996-01-16 2001-05-24 Rockefeller University, The DB the receptor for leptin nucleic acids encoding the receptor, and uses thereof
AU1833197A (en) 1996-01-18 1997-08-11 Progenitor, Inc. Detection of a leptin receptor variant and methods for regulating obesity
EP1731164A1 (en) 1996-01-23 2006-12-13 Indevus Pharmaceuticals, Inc. Methods for using the obese gene and its gene product to stimulate hematopoietic development
US7067472B1 (en) 1996-06-04 2006-06-27 The Scripps Research Institute Diagnostic and therapeutic methods related to regulating energy mobilization with OB protein and OB antibodies
US5965521A (en) 1997-02-25 1999-10-12 Eli Lilly Company Pulsatile delivery of leptin receptor ligands
IL120733A0 (en) 1997-04-29 1997-08-14 Yeda Res & Dev Leptin as an inhibitor of cell proliferation
US6696411B1 (en) 1998-04-22 2004-02-24 Cornell Research Foundation, Inc. Canine erythropoietin gene and recombinant protein
AU767068B2 (en) 1999-06-11 2003-10-30 Baylor College Of Medicine Methods and compositions for control of bone formation via modulation of leptin activity
US20040253242A1 (en) 2000-12-05 2004-12-16 Bowdish Katherine S. Rationally designed antibodies
FR2852397B1 (fr) 2003-03-10 2005-04-29 Utilisation des genes leprotl 1 et ob-rgrp pour le criblage de composes actifs sur la prise ou la perte de poids ou le diabete d'un sujet humain ou animal.
ATE364630T1 (de) * 2003-08-21 2007-07-15 Vlaams Interuniv Inst Biotech Neuer leptin-antagonist
US8969291B2 (en) 2004-10-08 2015-03-03 Enzo Therapeutics, Inc. Methods for decreasing leptin levels or activity for treating inflammation
US7863240B2 (en) 2004-10-08 2011-01-04 Enzo Therapeutics, Inc. Methods and uses of leptin in hepatocellular carcinoma
US7575878B2 (en) 2004-11-18 2009-08-18 Vib Vzw Methods of inhibiting leptin-induced signaling with fibronectin III domain antibodies
US7307142B2 (en) * 2004-11-26 2007-12-11 Yissum Research And Development Company Of The Hebrew University Of Jerusalem Leptin antagonists
JP5255435B2 (ja) 2005-04-26 2013-08-07 メディミューン，エルエルシー ヒンジドメイン操作による抗体エフェクター機能の調節
PE20071101A1 (es) 2005-08-31 2007-12-21 Amgen Inc Polipeptidos y anticuerpos
WO2008140603A2 (en) 2006-12-08 2008-11-20 Macrogenics, Inc. METHODS FOR THE TREATMENT OF DISEASE USING IMMUNOGLOBULINS HAVING FC REGIONS WITH ALTERED AFFINITIES FOR FCγR ACTIVATING AND FCγR INHIBITING
GB0715216D0 (en) 2007-08-03 2007-09-12 Asterion Ltd Leptin
CA2742968C (en) 2008-11-07 2020-06-09 Fabrus Llc Combinatorial antibody libraries and uses thereof
RU2620071C2 (ru) 2010-11-17 2017-05-22 Чугаи Сеияку Кабушики Каиша Мультиспецифическая связывающая антиген молекула, которая обладает альтернативной функцией к функции фактора свертывания крови viii
EP2672999A2 (en) 2011-02-10 2013-12-18 Roche Glycart AG Improved immunotherapy
US8790651B2 (en) 2011-07-21 2014-07-29 Zoetis Llc Interleukin-31 monoclonal antibody
US20140013456A1 (en) 2012-03-16 2014-01-09 Regeneron Pharmaceuticals, Inc. Histidine Engineered Light Chain Antibodies and Genetically Modified Non-Human Animals for Generating the Same
PL2895513T3 (pl) 2012-09-12 2018-11-30 Genzyme Corporation FC zawierające polipeptydy o zmienionej glikozylacji i zmniejszonej funkcji efektorowej
TWI682941B (zh) 2013-02-01 2020-01-21 美商再生元醫藥公司 含嵌合恆定區之抗體
SMT201800435T1 (it) * 2013-02-20 2018-09-13 Regeneron Pharma Animali non umani con sequenze della catena pesante dell’immunoglobulina modificate riferimento incrociato a domande correlate
ES2831014T3 (es) 2014-02-18 2021-06-07 Inst Nat Sante Rech Med Métodos y composiciones farmacéuticas para el tratamiento de enfermedades mediadas por la vía de señalización del complejo NRP-1/OBR
TWI752920B (zh) 2015-10-12 2022-01-21 美商再生元醫藥公司 活化瘦素受體的抗原結合蛋白
FI3538554T3 (fi) 2016-11-08 2025-09-24 Regeneron Pharma Antigeeniä sitovia proteiineja, jotka antagonisoivat leptiinireseptoria

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001501444A (ja) 1995-11-27 2001-02-06 ミレニウム ファーマシューティカルズ インク． Ｏｂ受容体ならびに体重障害の診断および治療の方法
JP2000504938A (ja) 1996-01-16 2000-04-25 ザ ロックフェラー ユニヴァーシティ Ｄｂ、レプチンのレセプター、そのレセプターをコードする核酸、及びこれらの使用
JP2007536212A (ja) 2003-11-17 2007-12-13 ルートヴィヒ マクシミリアン ウニヴェルジテート レプチンアンタゴニストおよびレプチン定量測定方法

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Biochemical and Biophysical Research Communications, 2014, Vol.452, pp.479-483
Journal of Immunological Methods, 2006, Vol.312, pp.190-200
The Journal of Clinical Endocrinology & Metabolism, 2000,Vol.85, pp.29-34

Also Published As

Publication number Publication date
AU2017359439B2 (en) 2024-11-28
US20180127508A1 (en) 2018-05-10
EP4613772A3 (en) 2025-12-24
FI3538554T3 (fi) 2025-09-24
IL266426A (en) 2019-06-30
SG10201913470SA (en) 2020-03-30
EA201991075A1 (ru) 2019-10-31
AU2025201454A1 (en) 2025-04-10
US20200123264A1 (en) 2020-04-23
SMT202500327T1 (it) 2025-11-10
MY203682A (en) 2024-07-12
MX2023011233A (es) 2023-10-03
CA3043365A1 (en) 2018-05-17
CL2020001023A1 (es) 2020-10-09
MX2019005397A (es) 2019-10-09
ES3040144T3 (en) 2025-10-28
US10550192B2 (en) 2020-02-04
KR20190075133A (ko) 2019-06-28
LT3538554T (lt) 2025-10-10
JP7611292B2 (ja) 2025-01-09
IL272358A (en) 2020-03-31
CO2019004672A2 (es) 2019-07-31
MY191256A (en) 2022-06-10
PT3538554T (pt) 2025-09-01
US20230235068A1 (en) 2023-07-27
EP3538554A1 (en) 2019-09-18
MA45801B1 (fr) 2021-11-30
US11535675B2 (en) 2022-12-27
UA127678C2 (uk) 2023-11-29
CN110167965A (zh) 2019-08-23
CL2020000549A1 (es) 2020-08-28
PH12019500988A1 (en) 2019-08-19
KR102563568B1 (ko) 2023-08-04
MA45801A1 (fr) 2020-07-29
PL3538554T3 (pl) 2025-10-27
DK3538554T3 (da) 2025-09-08
JP2024109952A (ja) 2024-08-14
IL272358B (en) 2022-02-01
JP2023093753A (ja) 2023-07-04
RS67214B1 (sr) 2025-10-31
WO2018089532A1 (en) 2018-05-17
EP3538554B1 (en) 2025-08-13
IL266426B (en) 2020-11-30
EP4613772A2 (en) 2025-09-10
SI3538554T1 (sl) 2025-10-30
CL2019001263A1 (es) 2019-09-27
JP2022031969A (ja) 2022-02-22
JP2020504078A (ja) 2020-02-06
HRP20251165T1 (hr) 2025-11-21
AU2017359439A1 (en) 2019-05-23

Similar Documents

Publication Publication Date Title
JP7759417B2 (ja) レプチン受容体を活性化させる抗原結合タンパク質
JP7611292B2 (ja) レプチン受容体をアンタゴナイズする抗原結合性タンパク質
CN104781280A (zh) 抗前动力蛋白受体(prokr)抗体及其使用
EA040524B1 (ru) Антигенсвязывающие белки, которые проявляют антагонизм в отношении лептинового рецептора
EA048830B1 (ru) Полинуклеотиды, кодирующие антитела, которые связываются с лептиновым рецептором, и способ получения таких антител

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20201027

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20201027

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20210827

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210903

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20211202

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20211221

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20220301

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20220315

R150 Certificate of patent or registration of utility model

Ref document number: 7042816

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250